MD-CANC ECOG-ACRIN Master
Source: ECOG-ACRIN Cancer Research Group
May 01, 2016 – April 30, 2028
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Source: Exelixis, Inc.
October 22, 2021 – October 21, 2024
MD-INMD-HO - Dreicer - JHU - J1823
Source: Johns Hopkins University, The
September 01, 2018 – December 31, 2023
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
Source: ECOG-ACRIN Cancer Research Group
September 01, 2018 – August 31, 2023
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Source: Seattle Genetics, Inc.
July 08, 2020 – July 07, 2023
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Source: Exelixis, Inc.
May 18, 2018 – May 17, 2023
Prostate Cancer Outcomes: An International Registry to ImproveOutcomes in Men with Advanced Prostate Cancer (IRONMAN)
Source: Prostate Cancer Clinical Trials Consortium, LLC
July 24, 2017 – April 24, 2023
MD-INMD-HO Dreicer - Endocyte - VISION
Source: Endocyte, Inc.
December 11, 2018 – December 10, 2022
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Source: Precog, LLC
November 14, 2018 – November 13, 2022
Master Agreement
Source: Coalition Of Cancer Cooperative Groups
August 01, 2000 – July 31, 2022
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer
Source: Janssen Research & Development, LLC
July 01, 2019 – June 30, 2022
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Source: ECOG-ACRIN Cancer Research Group
June 25, 2019 – June 24, 2022
MD-CANC-NRG Oncology Dreicer
Source: NRG Oncology Foundation, Inc.
February 09, 2016 – December 31, 2021
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-resistant Prostate Cancer and DNA-Repair Anomalies
Source: Janssen Scientific Affairs, L.L.C.
September 01, 2017 – October 31, 2021
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma ECTCN 9947
Source: Johns Hopkins University, The
December 01, 2016 – February 28, 2021
MD-INMD-HO Dreicer Clovis - ATLAS
Source: Clovis Oncology, Inc.
April 19, 2018 – July 14, 2020
MD-INMD-HO Phase I Study of C6 Ceramide Nanoliposome in Patients with Advanced Solid Tumors
Source: University Of Maryland
September 21, 2016 – November 22, 2019
MD-INMD Frontier Science and Technology Research Foundation Contract #PSAUVAGW00
Source: Frontier Science & Technology Research Foundation,
February 01, 2012 – January 31, 2018
MD-CANC The Johns Hopkins Phase 2 team for the ET-CTN Per Patient
Source: Johns Hopkins University, The
March 21, 2016 – February 28, 2017
MD-CANC The Johns Hopkins Phase 2 team for the ET-CTN Cost Reim. Travel
Source: Johns Hopkins University, The
March 21, 2016 – February 28, 2017
Phase III Study to Compare the Safety and Efficacy of TKI258 Versus Sorafenib
Source: Novartis Pharmaceuticals Corporation
August 09, 2010 – December 31, 2015
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)
Source: Medical University of South Carolina The
May 18, 2011 – May 17, 2015
MD-INMD An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway
Source: Novartis Pharmaceuticals Corporation
February 09, 2011 – September 10, 2014